Evidence map›Paper›PMID 41499296›Full record

Trial reportJournal of Huntington's disease2026

Assessing the efficacy of dextromethorphan/quinidine in treating irritability in Huntington's disease.

Shayan A Zadegan, Olivia Calderon, Nicholas Karagas, Jorge Patino, Deepa Dongarwar, Brittany Duncan, Antonio L Teixeira, Natalia P Rocha, Erin Furr Stimming

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Huntington's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shayan A ZadeganDepartment of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
Olivia CalderonBelfer Neurodegeneration Consortium, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Nicholas KaragasDepartment of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
Jorge PatinoDepartment of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
Deepa DongarwarDepartment of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
Brittany DuncanDepartment of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
Antonio L TeixeiraBiggs Institute, The University of Texas Health Science Center at San Antonio, Houston, TX, USA.
Natalia P RochaDepartment of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.ORCID 0000-0003-2616-8082
Erin Furr StimmingDepartment of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundHuntington's disease (HD) is a neurodegenerative disorder caused characterized by motor, cognitive, and psychiatric/behavioral impairments. Among these symptoms, irritability is particularly burdensome due to its frequency and significant impact on the daily lives of both patients and caregivers. Currently, no FDA-approved medication specifically targets this symptom.ObjectiveTo assess the efficacy of dextromethorphan/quinidine (DM/Q) 20/10 mg (NUEDEXTA

Indexed as

DextromethorphanExcitatory Amino Acid AntagonistsHuntington DiseaseIrritable MoodOutcome Assessment, Health CareQuinidineAdultCross-Over StudiesDouble-Blind MethodDrug CombinationsFemaleHumansMaleMiddle AgedTreatment OutcomeDextromethorphandextromethorphan - quinidine combinationDrug CombinationsExcitatory Amino Acid AntagonistsQuinidinedextromethorphanemotional dysregulationHuntington's diseaseirritabilityquinidine

Identifiers

PMID41499296
PMCPMC13396419

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.